The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Relevance of rise in CA15.3 during fulvestrant therapy in advanced breast cancer patients.
Amit Agrawal
No relevant relationships to disclose
B Balakrishnan
No relevant relationships to disclose
Kwok-Leung Cheung
Honoraria - AstraZeneca
John Forsyth Russell Robertson
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca